CNP200137 / CoBX Bio, Pharos iBio - LARVOL DELTA

Discovery of CNP200137, a second-generation menin-MLL inhibitor with superior preclinical properties and anti-leukemic activity against acquired resistance (AACR 2026) - "However, the emergence of on-target MEN1 resistance mutations has limited the long-term therapeutic benefits of first-generation agents such as revumenib and ziftomenib. In mice, the compounds exhibited an improved PK profile and strongly suppressed tumor growth in both parental and resistant MV4-11 xenografts. This novel, potent, and orally available second-generation menin–MLL inhibitor, CNP200137, represents a promising therapeutic strategy for overcoming acquired resistance in KMT2A-rearranged and NPM1-mutant acute leukemias."

Late-breaking abstract • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • KMT2A • MEIS1 • NPM1